Sugi Predict

Sugi Predict / Compounds / SCHEMBL15410380

SCHEMBL15410380

SCHEMBL15410380

N#Cc1ccc(NN)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ MAP2K1 Q02750 6/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ GAA P10253 2/20 0.42
▸ CSNK1D P48730 1/20 0.38
▸ CSNK1G2 P78368 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.38
▸ KAT2B Q92831 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ EGLN2 Q96KS0 2/20 0.36
▸ KIF11 P52732 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ACLY P53396 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL20984344 0.98 CA1 (0.44) CA1CA2CA9MAP2K1KDM4E
Hydrochloric Acid SCHEMBL11595853 0.98 CA1 (0.44) CA1CA2CA9MAP2K1KDM4E
Sulfuric Acid SCHEMBL20985029 0.90 CA1 (0.50) CA1CA2CA9MAP2K1USP30
Phosphoric Acid SCHEMBL20984583 0.90 MAP2K1 (0.43) CA1CA2CA9MAP2K1KDM4E
Oxalic Acid SCHEMBL20984652 0.90 MAP2K1 (0.49) CA1CA2CA9MAP2K1KDM4E
Oxalic Acid SCHEMBL20984650 0.90 MAP2K1 (0.49) CA1CA2CA9MAP2K1KDM4E
Nitric Acid SCHEMBL20984113 0.87 KMT2A (0.46) CA1CA2CA9MAP2K1USP30
SCHEMBL1141786 0.84 ACLY (0.41) CA1CA2CA9MAP2K1KDM4E
SCHEMBL12367896 0.80 MAP2K1 (0.42) MAP2K1KDM4EALDH1A1GAACSNK1D
SCHEMBL9232027 0.80 MAP2K1 (0.42) MAP2K1KDM4EALDH1A1GAACSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117682997-A Synthesis method of 3-fluoro-4- (1-pyrazole) -benzonitrile derivative 青岛科技大学 2024-03-12 — — CN claimed
US-20240226107-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 — — US disclosed
CN-117682997-A Synthesis method of 3-fluoro-4- (1-pyrazole) -benzonitrile derivative 青岛科技大学 2024-03-12 — — CN disclosed
CN-117682997-A Synthesis method of 3-fluoro-4- (1-pyrazole) -benzonitrile derivative 青岛科技大学 2024-03-12 — — CN disclosed
EP-4321515-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR Simcere Zaiming Pharmaceutical Co., Ltd. (CN) 2024-02-14 — — EP disclosed
CN-117136189-A Ubiquitin-specific protease 1 (USP 1) inhibitors 先声再明医药有限公司 2023-11-28 — — CN disclosed
WO-2022214053-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR 海南耀臻生物医药科技有限公司 2022-10-13 — — WO disclosed
US-11040938-B2 Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) 2021-06-22 — — US disclosed
US-20190152896-A1 Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) 2019-05-23 — — US disclosed
EP-3233833-B1 NOVEL COMPOUNDS CHIESI FARM SPA (IT) 2019-02-20 — — EP disclosed
EP-3233833-A1 NOVEL COMPOUNDS Chiesi Farmaceutici S.p.A. (IT) 2017-10-25 — — EP disclosed
CN-104428300-B The suppression of enzyme 奇斯药制品公司 2016-11-09 — — CN disclosed
EP-2872509-B1 INHIBITION OF ENZYMES CHIESI FARMA SPA (IT) 2016-09-14 — — EP disclosed
US-9409870-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2016-08-09 — — US disclosed
WO-2016096638-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2016-06-23 — — WO disclosed
US-20160168101-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2016-06-16 — — US disclosed
US-9199984-B2 Inhibition of enzymes CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-01 — — US disclosed
EP-2872509-A1 INHIBITION OF ENZYMES Chiesi Farmaceutici S.p.A. (IT) 2015-05-20 — — EP disclosed
US-20140018345-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A (IT) 2014-01-16 — — US disclosed
WO-2014009425-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A. (IT) 2014-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018345-A1 INHIBITION OF ENZYMES SERPINB1, ELANE, MPO CA1 861/4885CA2 1111/4885CA9 1102/4885
US-20240226107-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR USP1, USP2, USP3 CA1 1193/4885CA2 2994/4885CA9 2008/4885
US-11040938-B2 Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts HPD, TYR, PDK2 CA1 1443/4885CA2 931/4885CA9 1566/4885
US-20160168101-A1 NOVEL COMPOUNDS ELANE, SERPINB1, MPO CA1 4765/4885CA2 4496/4885CA9 3839/4885
US-20190152896-A1 Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts HPD, TYR, PDK2 CA1 1443/4885CA2 931/4885CA9 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.